

Trent M Woodruff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7842780/publications.pdf>

Version: 2024-02-01

215
papers

12,355
citations

23500

58
h-index

33814

99
g-index

244
all docs

244
docs citations

244
times ranked

15952
citing authors

#	ARTICLE	IF	CITATIONS
1	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	2.7	519
2	Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment. Brain, 2010, 133, 433-447.	3.7	497
3	Inflammasome inhibition prevents α -synuclein pathology and dopaminergic neurodegeneration in mice. Science Translational Medicine, 2018, 10, .	5.8	493
4	Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. Molecular Neurodegeneration, 2011, 6, 11.	4.4	431
5	T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4 ⁺ T cells. Science, 2016, 352, aad1210.	6.0	395
6	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	2.7	337
7	THE ROLE OF THE COMPLEMENT SYSTEM IN ISCHEMIA-REPERFUSION INJURY. Shock, 2004, 21, 401-409.	1.0	281
8	Inhibiting the C5a-C5a receptor axis. Molecular Immunology, 2011, 48, 1631-1642.	1.0	272
9	THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview. British Journal of Pharmacology, 2017, 174, S1-S16.	2.7	269
10	TOLL-LIKE RECEPTORS IN ISCHEMIA-REPERFUSION INJURY. Shock, 2009, 32, 4-16.	1.0	264
11	Treatment with a C5aR Antagonist Decreases Pathology and Enhances Behavioral Performance in Murine Models of Alzheimer's Disease. Journal of Immunology, 2009, 183, 1375-1383.	0.4	229
12	Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-evaluating the Evidence and the Myth. Journal of Immunology, 2015, 194, 3542-3548.	0.4	219
13	Eph/Ephrin Signaling in Injury and Inflammation. American Journal of Pathology, 2012, 181, 1493-1503.	1.9	199
14	C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB Journal, 2013, 27, 855-864.	0.2	181
15	Neutrophils: A Key Component of Ischemia-Reperfusion Injury. Shock, 2013, 40, 463-470.	1.0	178
16	Complement component 5a (C5a). International Journal of Biochemistry and Cell Biology, 2009, 41, 2114-2117.	1.2	149
17	The Complement Factor C5a Contributes to Pathology in a Rat Model of Amyotrophic Lateral Sclerosis. Journal of Immunology, 2008, 181, 8727-8734.	0.4	136
18	The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System. NeuroMolecular Medicine, 2010, 12, 179-192.	1.8	136

#	ARTICLE	IF	CITATIONS
19	The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. <i>Glia</i> , 2020, 68, 407-421.	2.5	133
20	Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. <i>FASEB Journal</i> , 2006, 20, 1407-1417.	0.2	129
21	The receptor for complement component C3a mediates protection from intestinal ischemia-reperfusion injuries by inhibiting neutrophil mobilization. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9439-9444.	3.3	128
22	COVID-19: Complement, Coagulation, and Collateral Damage. <i>Journal of Immunology</i> , 2020, 205, 1488-1495.	0.4	127
23	Complement mediators in ischemia-reperfusion injury. <i>Clinica Chimica Acta</i> , 2006, 374, 33-45.	0.5	118
24	Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. <i>Arthritis and Rheumatism</i> , 2002, 46, 2476-2485.	6.7	111
25	Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. <i>Neuroscience</i> , 2009, 158, 1074-1089.	1.1	110
26	A Potent Human C5a Receptor Antagonist Protects against Disease Pathology in a Rat Model of Inflammatory Bowel Disease. <i>Journal of Immunology</i> , 2003, 171, 5514-5520.	0.4	109
27	Complement activation in the injured central nervous system: another dual-edged sword?. <i>Journal of Neuroinflammation</i> , 2012, 9, 137.	3.1	108
28	Dendritic Cell Function in Allostimulation Is Modulated by C5aR Signaling. <i>Journal of Immunology</i> , 2009, 183, 6058-6068.	0.4	106
29	A New Small Molecule C5a Receptor Antagonist Inhibits the Reverse-Passive Arthus Reaction and Endotoxic Shock in Rats. <i>Journal of Immunology</i> , 2000, 164, 6560-6565.	0.4	103
30	Potent Cyclic Antagonists of the Complement C5a Receptor on Human Polymorphonuclear Leukocytes. Relationships between Structures and Activity. <i>Molecular Pharmacology</i> , 2004, 65, 868-879.	1.0	100
31	The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity. <i>Journal of Immunology</i> , 2019, 202, 3339-3348.	0.4	97
32	The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. <i>Journal of Immunology</i> , 2016, 196, 4783-4792.	0.4	94
33	The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury. <i>Journal of Neuroscience</i> , 2015, 35, 6517-6531.	1.7	90
34	Protective Effect of a New C5a Receptor Antagonist against Ischemia-Reperfusion Injury in the Rat Small Intestine. <i>Journal of Surgical Research</i> , 2002, 103, 260-267.	0.8	88
35	Generation of complement component C5a by ischemic neurons promotes neuronal apoptosis. <i>FASEB Journal</i> , 2012, 26, 3680-3690.	0.2	86
36	New tricks for an ancient system: Physiological and pathological roles of complement in the CNS. <i>Molecular Immunology</i> , 2018, 102, 3-13.	1.0	85

#	ARTICLE	IF	CITATIONS
37	Complement dysregulation in the central nervous system during development and disease. <i>Seminars in Immunology</i> , 2019, 45, 101340.	2.7	85
38	Developmental activities of the complement pathway in migrating neurons. <i>Nature Communications</i> , 2017, 8, 15096.	5.8	83
39	Processed foods drive intestinal barrier permeability and microvascular diseases. <i>Science Advances</i> , 2021, 7, .	4.7	80
40	Pharmacological inhibition of complement C5a ₁ receptor signalling ameliorates disease pathology in the hSOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 689-699.	2.7	79
41	Specific inhibition of NLRP3 in chikungunya disease reveals a role for inflammasomes in alphavirus-induced inflammation. <i>Nature Microbiology</i> , 2017, 2, 1435-1445.	5.9	77
42	Microglial C5aR (CD88) expression correlates with amyloid β deposition in murine models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2010, 113, 389-401.	2.1	76
43	Complement C5a inhibition reduces atherosclerosis in ApoE ^{-/-} mice. <i>FASEB Journal</i> , 2011, 25, 2447-2455.	0.2	76
44	Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 119.	3.1	76
45	Crosstalk between TGF β 1 and complement activation augments epithelial injury in pulmonary fibrosis. <i>FASEB Journal</i> , 2014, 28, 4223-4234.	0.2	76
46	Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. <i>Nature Communications</i> , 2016, 7, 12932.	5.8	75
47	Protective effects of a potent c5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. <i>Journal of Surgical Research</i> , 2004, 116, 81-90.	0.8	74
48	Complement: The Emerging Architect of the Developing Brain. <i>Trends in Neurosciences</i> , 2018, 41, 373-384.	4.2	73
49	Altered expression of metabolic proteins and adipokines in patients with amyotrophic lateral sclerosis. <i>Journal of the Neurological Sciences</i> , 2015, 357, 22-27.	0.3	70
50	Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 90.	3.1	69
51	Intrinsic bias at non-canonical, β -arrestin-coupled seven transmembrane receptors. <i>Molecular Cell</i> , 2021, 81, 4605-4621.e11.	4.5	69
52	Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. <i>Journal of Hepatology</i> , 2004, 40, 934-941.	1.8	68
53	Complement in Pregnancy: A Delicate Balance. <i>American Journal of Reproductive Immunology</i> , 2013, 69, 3-11.	1.2	68
54	Discovery of functionally selective C5aR2 ligands: novel modulators of C5a signalling. <i>Immunology and Cell Biology</i> , 2016, 94, 787-795.	1.0	68

#	ARTICLE	IF	CITATIONS
55	New concepts on the therapeutic control of complement anaphylatoxin receptors. <i>Molecular Immunology</i> , 2017, 89, 36-43.	1.0	67
56	Increased Potency of a Novel Complement Factor 5a Receptor Antagonist in a Rat Model of Inflammatory Bowel Disease. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 314, 811-817.	1.3	66
57	Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. <i>British Journal of Pharmacology</i> , 2008, 153, 1043-1053.	2.7	66
58	A Small Molecule Angiotensin II Type 2 Receptor (AT ₂ R) Antagonist Produces Analgesia in a Rat Model of Neuropathic Pain by Inhibition of p38 Mitogen-Activated Protein Kinase (MAPK) and p44/p42 MAPK Activation in the Dorsal Root Ganglia. <i>Pain Medicine</i> , 2013, 14, 1557-1568.	0.9	66
59	Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. <i>Seminars in Immunology</i> , 2016, 28, 292-308.	2.7	66
60	The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1. <i>Journal of Neuroscience</i> , 2016, 36, 5055-5070.	1.7	64
61	C5a receptor 1 promotes autoimmunity, neutrophil dysfunction and injury in experimental anti-myeloperoxidase glomerulonephritis. <i>Kidney International</i> , 2018, 93, 615-625.	2.6	64
62	Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. <i>ACS Omega</i> , 2020, 5, 2345-2354.	1.6	64
63	Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKC η . <i>Journal of Neuroscience</i> , 2017, 37, 5395-5407.	1.7	63
64	Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. <i>Journal of Neuroimmunology</i> , 2014, 276, 213-218.	1.1	60
65	Complement alone drives efficacy of a chimeric antigenococcal monoclonal antibody. <i>PLoS Biology</i> , 2019, 17, e3000323.	2.6	59
66	Complement receptor C3aR1 controls neutrophil mobilization following spinal cord injury through physiological antagonism of CXCR2. <i>JCI Insight</i> , 2019, 4, .	2.3	58
67	The Peripheral Immune System and Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 279.	1.1	57
68	Emerging Insights into the Structure and Function of Complement C5a Receptors. <i>Trends in Biochemical Sciences</i> , 2020, 45, 693-705.	3.7	57
69	C5a alters blood-brain barrier integrity in a human <i>in vitro</i> model of systemic lupus erythematosus. <i>Immunology</i> , 2015, 146, 130-143.	2.0	56
70	A novel anticonvulsant mechanism via inhibition of complement receptor C5aR1 in murine epilepsy models. <i>Neurobiology of Disease</i> , 2015, 76, 87-97.	2.1	55
71	Complement: Bridging the innate and adaptive immune systems in sterile inflammation. <i>Journal of Leukocyte Biology</i> , 2020, 108, 339-351.	1.5	55
72	Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis. <i>FASEB Journal</i> , 2016, 30, 2336-2350.	0.2	53

#	ARTICLE	IF	CITATIONS
73	Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis. <i>Cancer Letters</i> , 2022, 529, 70-84.	3.2	51
74	Mitochondrial C5aR1 activity in macrophages controls IL-1 β production underlying sterile inflammation. <i>Science Immunology</i> , 2021, 6, eabf2489.	5.6	50
75	Complement factor C5a as mast cell activator mediates vascular remodelling in vein graft disease. <i>Cardiovascular Research</i> , 2013, 97, 311-320.	1.8	49
76	Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. <i>Inflammation</i> , 2001, 25, 171-177.	1.7	48
77	Elevated complement factor C5a in maternal and umbilical cord plasma in preeclampsia. <i>Journal of Reproductive Immunology</i> , 2013, 97, 211-216.	0.8	48
78	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. <i>Diabetes</i> , 2020, 69, 83-98.	0.3	48
79	Comparative Agonist/Antagonist Responses in Mutant Human C5a Receptors Define the Ligand Binding Site. <i>Journal of Biological Chemistry</i> , 2005, 280, 17831-17840.	1.6	47
80	Brief Report: Complement C5a Promotes Human Embryonic Stem Cell Pluripotency in the Absence of FGF2. <i>Stem Cells</i> , 2014, 32, 3278-3284.	1.4	47
81	Complement in the fundamental processes of the cell. <i>Molecular Immunology</i> , 2017, 84, 17-25.	1.0	47
82	Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. <i>Biochemical Pharmacology</i> , 2020, 180, 114156.	2.0	47
83	The Role of the N-terminal Domain of the Complement Fragment Receptor C5L2 in Ligand Binding. <i>Journal of Biological Chemistry</i> , 2007, 282, 3664-3671.	1.6	46
84	Evidence that adiponectin receptor 1 activation exacerbates ischemic neuronal death. <i>Experimental & Translational Stroke Medicine</i> , 2010, 2, 15.	3.2	45
85	The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10. <i>British Journal of Pharmacology</i> , 2013, 168, 488-501.	2.7	45
86	Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3-4.	3.3	45
87	Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Skeletal Muscle</i> , 2017, 7, 10.	1.9	45
88	Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 171.	3.1	45
89	Monitoring C5aR2 Expression Using a Floxed tdTomato-C5aR2 Knock-In Mouse. <i>Journal of Immunology</i> , 2017, 199, 3234-3248.	0.4	44
90	The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. <i>Trends in Immunology</i> , 2020, 41, 965-967.	2.9	44

#	ARTICLE	IF	CITATIONS
91	C5a Receptor Signaling Prevents Folate Deficiency-Induced Neural Tube Defects in Mice. <i>Journal of Immunology</i> , 2013, 190, 3493-3499.	0.4	41
92	Leucocyte expression of complement C5a receptors exacerbates infarct size after myocardial reperfusion injury. <i>Cardiovascular Research</i> , 2014, 103, 521-529.	1.8	41
93	Low-Fouling Fluoropolymers for Bioconjugation and In Vivo Tracking. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 4729-4735.	7.2	40
94	Increased Placental Expression of Fibroblast Growth Factor 21 in Gestational Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E591-E598.	1.8	39
95	Systemic inhibition of the membrane attack complex impedes neuroinflammation in chronic relapsing experimental autoimmune encephalomyelitis. <i>Acta Neuropathologica Communications</i> , 2018, 6, 36.	2.4	39
96	Neural tube defects, folate, and immune modulation. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2013, 97, 602-609.	1.6	37
97	C5aR2 Activation Broadly Modulates the Signaling and Function of Primary Human Macrophages. <i>Journal of Immunology</i> , 2020, 205, 1102-1112.	0.4	37
98	Sustained-release ketamine-loaded nanoparticles fabricated by sequential nanoprecipitation. <i>International Journal of Pharmaceutics</i> , 2020, 581, 119291.	2.6	36
99	C5a induces caspase-dependent apoptosis in brain vascular endothelial cells in experimental lupus. <i>Immunology</i> , 2016, 148, 407-419.	2.0	35
100	Revisiting the role of the innate immune complement system in ALS. <i>Neurobiology of Disease</i> , 2019, 127, 223-232.	2.1	35
101	Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 126, 13-27.	1.3	34
102	The Alternative Receptor for Complement Component 5a, C5aR2, Conveys Neuroprotection in Traumatic Spinal Cord Injury. <i>Journal of Neurotrauma</i> , 2017, 34, 2075-2085.	1.7	34
103	Complement in stem cells and development. <i>Seminars in Immunology</i> , 2018, 37, 74-84.	2.7	34
104	Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1. <i>Journal of Biological Chemistry</i> , 2019, 294, 9416-9429.	1.6	34
105	Targeting ischemic brain injury with intravenous immunoglobulin. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 19-29.	1.5	33
106	Inhibition of Inflammation and Fibrosis by a Complement C5a Receptor Antagonist in DOCA-Salt Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2011, 58, 479-486.	0.8	33
107	Placental Lipases in Pregnancies Complicated by Gestational Diabetes Mellitus (GDM). <i>PLoS ONE</i> , 2014, 9, e104826.	1.1	33
108	A potent and selective inhibitor of group IIa secretory phospholipase A2 protects rats from TNBS-induced colitis. <i>International Immunopharmacology</i> , 2005, 5, 883-892.	1.7	32

#	ARTICLE	IF	CITATIONS
109	Antiallodynic effects of alpha lipoic acid in an optimized <sc>RR</sc>â€<sc>EAE</sc> mouse model of <sc>MS</sc>â€™ neuropathic pain are accompanied by attenuation of upregulated <sc>BDNF</sc>â€™<sc>ERK</sc> signaling in the dorsal horn of the spinal cord. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00137.	1.1	32
110	Serping1/C1 Inhibitor Affects Cortical Development in a Cell Autonomous and Non-cell Autonomous Manner. <i>Frontiers in Cellular Neuroscience</i> , 2017, 11, 169.	1.8	32
111	De Novo Peptide Design with C3a Receptor Agonist and Antagonist Activities: Theoretical Predictions and Experimental Validation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4159-4168.	2.9	31
112	Inflammasomes in CNS Diseases. <i>Experientia Supplementum</i> (2012), 2018, 108, 41-60.	0.5	31
113	Cholesterol Crystals Induce Coagulation Activation through Complement-Dependent Expression of Monocytic Tissue Factor. <i>Journal of Immunology</i> , 2019, 203, 853-863.	0.4	31
114	Complement inhibitors selectively attenuate injury following administration of cobra venom factor to rats. <i>International Immunopharmacology</i> , 2006, 6, 1224-1232.	1.7	30
115	The Ketone Body Î²-Hydroxybutyrate Does Not Inhibit Synuclein Mediated Inflammasome Activation in Microglia. <i>Journal of NeuroImmune Pharmacology</i> , 2017, 12, 568-574.	2.1	30
116	Complement C5a Receptor 1 Exacerbates the Pathophysiology of<i>N.Âmeningitidis</i>Sepsis and Is a Potential Target for Disease Treatment. <i>MBio</i> , 2018, 9, .	1.8	30
117	Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. <i>Molecular Immunology</i> , 2018, 101, 176-181.	1.0	30
118	Gut microbiota in ALS: possible role in pathogenesis?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 785-805.	1.4	30
119	The complement cascade in the regulation of neuroinflammation, nociceptive sensitization, and pain. <i>Journal of Biological Chemistry</i> , 2021, 297, 101085.	1.6	29
120	Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2008, 632, 143-58.	0.8	27
121	Monocytes and neutrophils are associated with clinical features in amyotrophic lateral sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa013.	1.5	26
122	Staphylococcus aureusâ€™induced complement activation promotes tissue factorâ€™mediated coagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 905-918.	1.9	25
123	Pivotal role for beta-1 integrin in neurovascular remodelling after ischemic stroke. <i>Experimental Neurology</i> , 2010, 221, 107-114.	2.0	24
124	Properdin Provides Protection from <i>Citrobacter rodentium</i>â€™Induced Intestinal Inflammation in a C5a/IL-6â€™Dependent Manner. <i>Journal of Immunology</i> , 2015, 194, 3414-3421.	0.4	24
125	C5aR1 regulates T follicular helper differentiation and chronic graft-versus-host disease bronchiolitis obliterans. <i>JCI Insight</i> , 2018, 3, .	2.3	24
126	T Cell Expression of C5a Receptor 2 Augments Murine Regulatory T Cell (TREG) Generation and TREG-Dependent Cardiac Allograft Survival. <i>Journal of Immunology</i> , 2018, 200, 2186-2198.	0.4	23

#	ARTICLE	IF	CITATIONS
127	C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma. <i>FASEB Journal</i> , 2019, 33, 11060-11071.	0.2	23
128	Distinct roles of the anaphylatoxin receptors C3aR, C5aR1 and C5aR2 in experimental meningococcal infections. <i>Virulence</i> , 2019, 10, 677-694.	1.8	23
129	Pharmacokinetics of a C5a receptor antagonist in the rat after different sites of enteral administration. <i>European Journal of Pharmaceutical Sciences</i> , 2008, 33, 390-398.	1.9	22
130	Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. <i>Journal of Periodontal Research</i> , 2011, 46, 643-647.	1.4	22
131	Complement C5a Regulates Proinflammatory Mediators in Human Placenta. <i>Biology of Reproduction</i> , 2012, 86, 190.	1.2	22
132	Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. <i>Human Molecular Genetics</i> , 2016, 25, 1780-1791.	1.4	22
133	Low fouling fluoropolymers for bioconjugation and in vivo tracking. <i>Angewandte Chemie</i> , 2020, 132, 4759-4765.	1.6	22
134	Insights into the mechanism of C5aR inhibition by PMX53 via implicit solvent molecular dynamics simulations and docking. <i>BMC Biophysics</i> , 2014, 7, 5.	4.4	21
135	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. <i>Scientific Reports</i> , 2018, 8, 8101.	1.6	21
136	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2019, 16, 45.	3.1	21
137	Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2020, 57, 4143-4155.	1.9	21
138	The role of the ribosomal protein S19 C-terminus in Gi protein-dependent alternative activation of p38 MAP kinase via the C5a receptor in HMC-1 cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 966-981.	2.2	20
139	Comparative efficacy of a secretory phospholipase A2 inhibitor with conventional anti-inflammatory agents in a rat model of antigen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2011, 13, R42.	1.6	20
140	Co-ordinated expression of innate immune molecules during mouse neurulation. <i>Molecular Immunology</i> , 2015, 68, 253-260.	1.0	19
141	Release of bioactive peptides from polyurethane films in vitro and in vivo: Effect of polymer composition. <i>Acta Biomaterialia</i> , 2016, 41, 264-272.	4.1	19
142	Complement factors C3a and C5a have distinct hemodynamic effects in the rat. <i>International Immunopharmacology</i> , 2009, 9, 800-806.	1.7	17
143	The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres. <i>Journal of Neuroinflammation</i> , 2009, 6, 34.	3.1	17
144	A Commentary On: β -Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer's Disease: A cautionary note regarding C3aR. <i>Frontiers in Immunology</i> , 2015, 6, 220.	2.2	17

#	ARTICLE	IF	CITATIONS
145	Autoantibodies against homocysteinylated protein in a mouse model of folate deficiency-induced neural tube defects. <i>Birth Defects Research Part A: Clinical and Molecular Teratology</i> , 2016, 106, 201-207.	1.6	17
146	Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration. <i>Journal of Immunology</i> , 2020, 205, 2834-2839.	0.4	17
147	Derivation of ligands for the complement C3a receptor from the C-terminus of C5a. <i>European Journal of Pharmacology</i> , 2014, 745, 176-181.	1.7	16
148	Deletion of Biliverdin Reductase A in Myeloid Cells Promotes Chemokine Expression and Chemotaxis in Part via a Complement C5a-C5aR1 Pathway. <i>Journal of Immunology</i> , 2019, 202, 2982-2990.	0.4	16
149	Epha4-Fc Treatment Reduces Ischemia/Reperfusion-Induced Intestinal Injury by Inhibiting Vascular Permeability. <i>Shock</i> , 2016, 45, 184-191.	1.0	15
150	TDP-43 Puts the STING in ALS. <i>Trends in Neurosciences</i> , 2021, 44, 81-82.	4.2	14
151	Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor 1 Abbreviations: C5aR, human complement fragment 5a receptor; WT, wild-type; G105D, C5aR mutated to aspartate at glycine105; P103Y, C5aR mutated to tyrosine at proline105; P103Y/G105D, C5aR containing both substitutions; C5adR74, des arginated C5a; F-[OPchaWR], phenylalanine [l-ornithine-proline-d-cyclohexylalanine-tryptophan-arginine]; MeFKPchaWr, N-methylphenylalanine-lysine-proline-d-cyclohexylalanine. <i>Biochemical Pharmacology</i> , 2001, 63, 107-115.	2.0	13
152	Properdin deficiency protects from 5-fluorouracil-induced small intestinal mucositis in a complement activation-independent, interleukin-10-dependent mechanism. <i>Clinical and Experimental Immunology</i> , 2017, 188, 36-44.	1.1	12
153	Acetate protects against intestinal ischemia-reperfusion injury independent of its cognate free fatty acid 2 receptor. <i>FASEB Journal</i> , 2020, 34, 10418-10430.	0.2	12
154	A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. <i>Journal of Neurochemistry</i> , 2021, 158, 807-817.	2.1	12
155	Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. <i>Amino Acids</i> , 2021, 53, 143-147.	1.2	12
156	Recent developments in C5/C5a inhibitors. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 445-458.	2.4	11
157	The C3aR Antagonist SB290157 is a Partial C5aR2 Agonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 591398.	1.6	11
158	Role of Complement in Motor Neuron Disease: Animal Models and Therapeutic Potential of Complement Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2008, , 136-151.	0.8	11
159	Placental lipase expression in pregnancies complicated by preeclampsia: a case-control study. <i>Reproductive Biology and Endocrinology</i> , 2015, 13, 100.	1.4	10
160	Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis. <i>Cellular and Molecular Immunology</i> , 2020, 17, 1010-1013.	4.8	9
161	Glucose clearance and uptake is increased in the SOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis through an insulin-independent mechanism. <i>FASEB Journal</i> , 2021, 35, e21707.	0.2	9
162	The emerging role of complement in neuromuscular disorders. <i>Seminars in Immunopathology</i> , 2021, 43, 817-828.	2.8	9

#	ARTICLE	IF	CITATIONS
163	Transdermal Pharmacology of Small Molecule Cyclic C5a Antagonists. , 2006, 586, 329-345.		8
164	Phagocytosis of live and dead Escherichia coli and Staphylococcus aureus in human whole blood is markedly reduced by combined inhibition of C5aR1 and CD14. Molecular Immunology, 2019, 112, 131-139.	1.0	8
165	The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. FASEB Journal, 2020, 34, 7225-7233.	0.2	8
166	An Immunoregulatory Role for Complement Receptors in Murine Models of Breast Cancer. Antibodies, 2021, 10, 2.	1.2	8
167	C5a-C5aR1 Axis Activation Drives Envenomation Immunopathology by the Snake Naja annulifera. Frontiers in Immunology, 2021, 12, 652242.	2.2	8
168	Complement factor 5a as a therapeutic target. Drugs of the Future, 2006, 31, 325.	0.0	8
169	Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. Journal of Medicinal Chemistry, 2021, 64, 16598-16608.	2.9	8
170	Neuroinflammation as a therapeutic target in neurodegenerative diseases. , 2017, , 49-80.		7
171	Anaphylatoxin receptor promiscuity for commonly used complement C5a peptide agonists. International Immunopharmacology, 2021, 100, 108074.	1.7	7
172	Reduced Growth, Altered Gut Microbiome and Metabolite Profile, and Increased Chronic Kidney Disease Risk in Young Pigs Consuming a Diet Containing Highly Resistant Protein. Frontiers in Nutrition, 2022, 9, 816749.	1.6	7
173	Increased expression of C5a receptor (CD88) mRNA in canine mammary tumors. Veterinary Immunology and Immunopathology, 2011, 139, 50-56.	0.5	6
174	Noninvasive assessment of altered activity following restraint in mice using an automated physiological monitoring system. Stress, 2017, 20, 76-84.	0.8	6
175	Chronic Helminth Infection Perturbs the Gut-Brain Axis, Promotes Neuropathology, and Alters Behavior. Journal of Infectious Diseases, 2018, 218, 1511-1516.	1.9	6
176	Characterisation of small molecule ligands 4CMTB and 2CTAP as modulators of human FFA2 receptor signalling. Scientific Reports, 2018, 8, 17819.	1.6	6
177	Complement component 5 does not interfere with physiological hemostasis but is essential for Escherichia coli-induced coagulation accompanied by Toll-like receptor 4. Clinical and Experimental Immunology, 2019, 196, 97-110.	1.1	6
178	De novo protein design of agonists and antagonists of C5a receptors. Immunobiology, 2012, 217, 1162-1163.	0.8	5
179	Air Bubbles Activate Complement and Trigger Hemostasis and C3-Dependent Cytokine Release Ex Vivo in Human Whole Blood. Journal of Immunology, 2021, 207, 2828-2840.	0.4	5
180	In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. ACS Pharmacology and Translational Science, 2022, 5, 41-51.	2.5	5

#	ARTICLE	IF	CITATIONS
181	Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
182	The Receptor for Advanced Glycation Endproducts Does Not Contribute to Pathology in a Mouse Mesenteric Ischemia/Reperfusion-Induced Injury Model. <i>Frontiers in Immunology</i> , 2015, 6, 614.	2.2	4
183	The Role of C5a Receptor Signaling in Endotoxin-Induced Miscarriage and Preterm Birth. <i>American Journal of Reproductive Immunology</i> , 2015, 74, 148-155.	1.2	4
184	Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain. <i>Molecular Immunology</i> , 2018, 94, 68-74.	1.0	4
185	Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2022, 23, 430-437.	1.1	4
186	Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays <i>in Vitro</i> and <i>in Vivo</i> . <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1808-1817.	2.5	4
187	Complement drives circuit modulation in the adult brain. <i>Progress in Neurobiology</i> , 2022, 214, 102282.	2.8	4
188	Is the C3a receptor antagonist SB290157 a useful pharmacological tool?. <i>British Journal of Pharmacology</i> , 2020, 177, 5677-5678.	2.7	3
189	Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement. <i>Frontiers in Neurology</i> , 2020, 11, 577272.	1.1	3
190	Optimisation of a Microfluidic Method for the Delivery of a Small Peptide. <i>Pharmaceutics</i> , 2021, 13, 1505.	2.0	3
191	Complement expression in mice throughout neural tube closure. <i>Molecular Immunology</i> , 2010, 47, 2251-2251.	1.0	2
192	A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. <i>Immunobiology</i> , 2016, 221, 1209.	0.8	2
193	Commentary: Beyond C4: Analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls. <i>Frontiers in Immunology</i> , 2019, 10, 2853.	2.2	2
194	Editorial: The Role of Complement in Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 139.	2.2	2
195	C5aR protects against folate-deficiency induced neural tube defects in mice. <i>Molecular Immunology</i> , 2010, 47, 2254-2254.	1.0	1
196	Complement peptide receptors in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	1
197	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages. <i>Journal of Immunology</i> , 2022, 208, 133-142.	0.4	1
198	Thrombin Differentially Modulates the Acute Inflammatory Response to <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> in Human Whole Blood. <i>Journal of Immunology</i> , 2022, 208, 2771-2778.	0.4	1

#	ARTICLE	IF	CITATIONS
199	The receptor for complement anaphylatoxin C5a protects against the development of airway hyperresponsiveness in allergic asthma by inhibiting cysteinyl leukotriene pathway. <i>Molecular Immunology</i> , 2008, 45, 4109-4110.	1.0	0
200	The role of C5a in reproductive impairment in the mouse and human. <i>Molecular Immunology</i> , 2008, 45, 4150.	1.0	0
201	Protective effects of C5a receptor antagonism in a mouse model of atherosclerosis. <i>Molecular Immunology</i> , 2008, 45, 4151.	1.0	0
202	Dysregulation of the complement system in neurodegenerative disease. <i>Molecular Immunology</i> , 2010, 47, 2270-2270.	1.0	0
203	The role of complement anaphylatoxin receptors in mesenteric ischemia/reperfusion-induced injury. <i>Molecular Immunology</i> , 2010, 47, 2270-2270.	1.0	0
204	Antagonizing C5aR Reduces T Cell- IL-10-Dependent Colitis in Pre-Clinical Models. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S110.	0.9	0
205	Innate Immunity in ALS. , 0, , .		0
206	Motor neuron disease proteins activate complement and generate C5a. <i>Molecular Immunology</i> , 2017, 89, 168.	1.0	0
207	C5aR1 is required for α -synuclein mediated NLRP3 inflammasome activation in microglia: Implications for Parkinson's disease. <i>Molecular Immunology</i> , 2018, 102, 229.	1.0	0
208	C3aR1. , 2018, , 385-396.		0
209	C5aR2. , 2018, , 407-414.		0
210	Stimulating the Activity of NEP and ACE2: A Unique Approach to Prevent Dementia. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
211	IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY. <i>Neuro-Oncology</i> , 2021, 23, i28-i29.	0.6	0
212	Neuroinflammation in Huntingtonâ€™s. <i>Neuromethods</i> , 2022, , 215-233.	0.2	0
213	Complement peptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	0
214	Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	3.0	0
215	Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2020, 2020, .	0.2	0